Sana says NEJM publishes 14-month data supporting hypoimmune islet transplant in type 1 diabetes without immunosuppression

Sana Biotechnology, Inc.

Sana Biotechnology, Inc.

SANA

0.00
  • Sana Biotechnology highlighted NEJM publication of 14-month follow-up data for UP421 hypoimmune-modified islet cell transplant in type 1 diabetes.
  • Study reported continued insulin production without immunosuppression, with circulating C-peptide present at month 14 versus undetectable at baseline.
  • No safety issues were identified; imaging at 52 weeks showed islet cells at the forearm muscle transplant site.
  • Sana expects to file an IND and start a Phase 1/2 trial as early as this year for SC451, a stem cell-derived HIP-modified therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9760965) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.